Background The use of antipsychotic medication in the United States and throughout the
world has greatly increased over the last fifteen years. These drugs have significant side …

This is a study of the metabolic and distal cardiovascular/cerebrovascular outcomes
associated with the use of second‐generation antipsychotics (SGAs) compared to …

People with schizophrenia are at considerably higher risk of cardiometabolic morbidity than
the general population. Second-generation antipsychotic drugs contribute to that risk partly …

Schizophrenia is characterized by a wide spectrum of clinical manifestations, including
strong effects on mood and behavior. Patients can also suffer from serious comorbidities …

Background: Atypical antipsychotics can induce metabolic side effects, but whether they are
dose-dependent remains unclear. Objective: To assess the effect of risperidone and/or …

Atypical antipsychotics produce severe side effects including myocarditis that may be
attributed to oxidative stress. The aim of this study was to investigate the influence of …

Abstract Introduction Type 2 diabetes (T2D) is a common comorbidity in patients with
schizophrenia (SCZ). The underlying pathophysiologic mechanisms are yet to be fully …

Antipsychotics (APs) are associated with weight gain and other metabolic abnormalities
such as hyperglycemia, dyslipidemia and metabolic syndrome. This translational study …

Background Several psychotropic drugs can induce weight gain and metabolic alterations.
The authors compared metabolic evolutions of patients switching versus continuing …

Atypical antipsychotics have become a common therapeutic option in both schizophrenia
and bipolar disorder. However, these medications come with a high risk of metabolic side …